Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,567.00-0.24%ETH$2,697.69-0.48%GOLD$4,194.10+0.17%OIL$90.00+0.63%
Smart Investors Daily
SID Premium
CL

AMEX · CLDI

Calidi Biotherapeutics, Inc.

Healthcare · Biotechnology

$1.05

Down-$0.03 (-2.86%)

Updated Oct 7, 2026, 12:01 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.39M
P/E ratio
-0.28
Dividend yield
0.00%
52-week range
$0.10 – $1.93
Volume
22.04K
Avg. volume
161.89K

Price performance · CLDI

CLDI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

CLDI closed at $1.05 after 20 trading sessions, down 22.22% for the selected period.

Last close
$1.05
Period change
-22.22%
Period low
$1.05
Period high
$1.36
Daily close
View OHLC price history
CLDI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$1.08$1.1199$1.00$1.0522.04K
Oct 2, 2026$1.09$1.09$1.05$1.0838.62K
Oct 1, 2026$1.065$1.08$1.05$1.0815.03K
Sep 30, 2026$1.08$1.095$1.05$1.0749.29K
Sep 29, 2026$1.075$1.08$1.03$1.0843.96K
Sep 28, 2026$1.10$1.13$1.05$1.07154.9K
Sep 25, 2026$1.20$1.2899$1.13$1.13129.89K
Sep 24, 2026$1.15$1.25$1.10$1.20593.5K
Sep 23, 2026$1.10$1.15$1.05$1.092.88M
Sep 22, 2026$1.1109$1.1499$1.11$1.1137.29K
Sep 21, 2026$1.11$1.163$1.10$1.112333.52K
Sep 18, 2026$1.28$1.28$1.10$1.1032.66K
Sep 17, 2026$1.15$1.29$1.05$1.27190.88K
Sep 16, 2026$1.22$1.23$1.16$1.1732.44K
Sep 15, 2026$1.21$1.22$1.17$1.1734.34K
Sep 14, 2026$1.27$1.27$1.21$1.2220.17K
Sep 11, 2026$1.24$1.28$1.22$1.2470.66K
Sep 10, 2026$1.31$1.34$1.30$1.3132.47K
Sep 9, 2026$1.33$1.37$1.3007$1.3646.04K
Sep 8, 2026$1.38$1.3997$1.2501$1.3531.39K

Latest CLDI news

The latest Smart Investors Daily articles mentioning CLDI.

Stock researchCompany · Overview

CLDI research

Overview

Company profile and research snapshot.

Company profile

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.50
Implied upside
—
Analysts
—
CLDI recent ratings
DateFirmRatingTarget
Jun 27, 2024Ladenburg ThalmannBuy—
May 15, 2024BairdOutperform—
Mar 21, 2024HC Wainwright & Co.Buy—
Mar 21, 2024BairdOutperform—
Nov 22, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that on September 21, 2026, the Company received a notice (the “Notice”) from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(ii)of the NYSE American C

Yahoo · Sep 17, 2026

Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it has entered into a definitive stock purchase agreement with certain accredited investors and/or qualified institutional buyers for the purchase and sale of 1,025,640 shares of the Company’s common stock, in a registered direct offering, at a per share purchase price o

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By